Glucocorticoid Therapy Decreases Serum Lipoprotein(a) Concentration in Rheumatic Diseases.

スポンサーリンク

概要

• 論文の詳細を見る

• Lipoprotein(a) has been strongly suggested to be a risk factor for atherosclerosis. However, its metabolism and/or regulation by drug treatment still remain unknown.Wetherefore studied the effects of glucocorticoid therapy on serum lipoprotein(a) in rheumatic diseases. Although the glucocorticoid treatment increased the total serum cholesterol, high-density lipoprotein cholesterol and apolipoprotein B concentrations, it reduced the serum lipoprotein(a) concentration (mean, 40%) in a dose-dependent manner in 9 patients with rheumatic diseases without nephrotic syndrome. Similar results were observed in 2 patients who did have nephrotic syndrome. It is assumed that the increase of total cholesterol and apolipoprotein B in serum levels are atherogenic, whereas the increase of high-density lipoprotein cholesterol and the decrease of lipoprotein(a) are protective for atherosclerosis. The clinical outcome of the concomitant results in lipid metabolism in the development of atherosclerosis remains to be studied.(Internal Medicine 32: 382-386, 1993)

• 社団法人　日本内科学会の論文

著者

• KAWAI Shinichi

  the Institute of Medical Science, St. Marianna University School of Medicine

• Kawai Shinichi

  The Institute Of Medical Science St. Marianna University School Of Medicine

• AOKI Kazutoshi

  the Second Department of Internal Medicine, Saitama Medical Center, Saitama Medical School

関連論文

• Phospholipid-Dependent Anti-β_2-Glycoprotein I (β_2-GPI) Antibodies and Antiphospholipid Syndrome
• Glucocorticoid Therapy Decreases Serum Lipoprotein(a) Concentration in Rheumatic Diseases.
• Integrin VLA-5 Negative Primary Plasma Cell Leukemia.

スポンサーリンク